BridgeMD
IRONGIRLS-PILOT: Feasibility of Alternate-Day Iron Supplementation in Adolescent Girls
EU CTIS ID: 2025-522498-12-00
What this study is testing
1. To evaluate the feasibility of Duroferon 100 mg administered on alternate days in combination with Iron Smart, compared with placebo plus Iron Smart, in adolescent girls with iron deficiency. 2. To evaluate the diagnostic performance of IRON-5 in identifying iron deficiency (ferritin <15 µg/L).
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Student at Polhemskolan, Lund
- Age ≥15 years
- Post-menarcheal
- Written informed consent from the participant
- Written informed consent from legal guardian(s) if <18 years
- Serum ferritin <30 µg/L
You likely can't join if
- Pregnancy
- Chronic inflammatory disease (e.g. rheumatoid arthritis, Crohn’s disease)
- Ongoing acute infection (e.g. tonsillitis, urinary tract infection)
- CRP >10 mg/L
- Current iron supplementation (except multivitamins)
- Anaemia (Hb <110 g/L if <18 years; <117 g/L if ≥18 years, according to regional reference limits)
See the full eligibility criteria
- Student at Polhemskolan, Lund
- Age ≥15 years
- Post-menarcheal
- Written informed consent from the participant
- Written informed consent from legal guardian(s) if <18 years
- Serum ferritin <30 µg/L
- Pregnancy
- Chronic inflammatory disease (e.g. rheumatoid arthritis, Crohn’s disease)
- Ongoing acute infection (e.g. tonsillitis, urinary tract infection)
- CRP >10 mg/L
- Current iron supplementation (except multivitamins)
- Anaemia (Hb <110 g/L if <18 years; <117 g/L if ≥18 years, according to regional reference limits)
- Iron overload (serum ferritin >150 µg/L; WHO definition)
- Clinically significant vitamin B12 deficiency requiring immediate medical evaluation or treatment (e.g. serum vitamin B12 <150 pmol/L).
- Use of medication known to interfere with iron absorption or cause clinically significant interaction with oral iron (e.g. fluoroquinolones, tetracyclines, bisphosphonates, levodopa, methyldopa, aluminium- or magnesium-containing antacids), defined as regular or daily use (≥3 times per week).
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.